Intrinsic signal amplification by type III CRISPR-Cas systems provides a sequence-specific SARS-CoV-2 diagnostic
Andrew Santiago‐Frangos, L Hall, Anna Nemudraia, Artem Nemudryi, Pushya Krishna, Tanner Wiegand, Royce A. Wilkinson, Deann T. Snyder, Jodi F. Hedges, Calvin Cicha, Helen Lee, Ava B. Graham, Mark A. Jutila, Matthew P. Taylor, Blake Wiedenheft
Abstract
copies/μL for ten guides. To decrease the limit of detection to levels that are clinically relevant, we developed a two-pot reaction consisting of RT-LAMP followed by T7-transcription and type III CRISPR-based detection. The two-pot reaction has a sensitivity of 200 copies/μL and is completed using patient samples in less than 30 min.
Topics & Concepts
CRISPRSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Sequence (biology)Coronavirus disease 2019 (COVID-19)SIGNAL (programming language)VirologyComputational biologyBiologyComputer scienceGeneticsMedicineProgramming languageGenePathologyInfectious disease (medical specialty)DiseaseCRISPR and Genetic EngineeringSARS-CoV-2 and COVID-19 ResearchAdvanced biosensing and bioanalysis techniques